{"id":"NCT04918771","sponsor":"Materia Medica Holding","briefTitle":"Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old","officialTitle":"Multicenter Double Blind Placebo-controlled Parallel-group Randomized Clinical Study of Efficacy and Safety of Raphamin in the Treatment of Acute Respiratory Viral Infection in Children Aged 12-18 Years Old","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-04-29","primaryCompletion":"2023-07-21","completion":"2023-07-21","firstPosted":"2021-06-09","resultsPosted":"2024-10-15","lastUpdate":"2024-10-15"},"enrollment":435,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Respiratory Viral Infection"],"interventions":[{"type":"DRUG","name":"Raphamin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Raphamin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The multicenter double-blind placebo-controlled randomized in parallel-group. The objective of this study is to evaluate efficacy and safety of Raphamin in the treatment of acute respiratory viral infection (ARVI) in children aged 12-18 years old.","primaryOutcome":{"measure":"Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).","timeFrame":"14 days of observation","effectByArm":[{"arm":"Raphamin","deltaMin":3.3,"sd":1.7},{"arm":"Placebo","deltaMin":4.4,"sd":2.6}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":206},"commonTop":["Flu","Adenoiditis","Bacterial superinfection","Viral upper respiratory tract infection","Coronavirus infection COVID-19"]}}